The Diagnostic clinical Interview for Drug Withdrawal 1 (DID-W1) – New Symptoms of Selective Serotonin Reuptake Inhibitors (SSRI) or Serotonin Norepinephrine Reuptake Inhibitors (SNRI): inter-rater reliability

La Diagnostic clinical Interview for Drug Withdrawal 1 (DID-W1) – New Symptoms of Selective Serotonin Reuptake Inhibitors (SSRI) or Serotonin Norepinephrine Reuptake Inhibitors (SNRI): affidabilità fra valutatori

FIAMMETTA COSCI1,2, GUY CHOUINARD3,4, VIRGINIE-ANNE CHOUINARD5, GIOVANNI ANDREA FAVA6,7
E-mail: fiammetta.cosci@unifi.it

1Department of Health Sciences, University of Florence, Italy
2Department of Psychiatry & Neuropsychology, Maastricht University, The Netherlands
3Clinical Psychopharmacology and Therapeutics Unit, Montréal, Québec, Canada
4University Mental Health Institute of Montreal, Research Center Fernand Seguin, University of Montréal, Québec, Canada
5Psychotic Disorders Division, McLean Hospital, Harvard Medical School, Belmont, USA
6Department of Psychology, University of Bologna, Italy
7State University of New York at Buffalo, Buffalo, New York, USA

SUMMARY. Aim. A wide range of clinical phenomena have been reported with dose reduction or drug discontinuation of Selective Serotonin Reuptake Inhibitors (SSRIs) or Serotonin Norepinephrine Reuptake Inhibitors (SNRIs). In 2015, a new classification of SSRIs/SNRIs withdrawal (i.e., new withdrawal symptoms, rebound symptoms withdrawal, persistent post-withdrawal disorders) was outlined on the basis of the literature and clinical observations. A semistructured clinical interview, the Diagnostic clinical Interview for Drug Withdrawal 1 - New Symptoms of SSRI and SNRI (DID-W1), was developed for identifying and differentiating such syndromes. Its inter-rater reliability has been tested. Methods. Seventeen consecutive outpatients with a history of SSRI or SNRI dose reduction or discontinuation were assessed independently by 2 clinicians at different times during the same day. Percent agreement, Cohen’s kappa, and the squared correlation coefficient were used to measure inter-rater reliability. Results. The percent agreement for the whole interview was 97.06%, the Cohen’s kappa 0.85 (95% CI of 0.61-1.08), the squared correlation coefficient 0.72. Discussion and conclusions. The kappa values indicated excellent inter-rater agreement. Validity evaluation and comparison with other instruments need to be performed. The DID-W1 may help diagnosing the clinical phenomena related to SSRI and SNRI discontinuation, their differentiation from relapse, and the potential iatrogenic origin of psychiatric symptoms in clinical practice.

KEY WORDS: withdrawal, selective serotonin reuptake inhibitor, serotonin norepinephrine reuptake inhibitor, interview, reliability, iatrogenic comorbidity.

RIASSUNTO. Scopo. Dopo la riduzione della dose o la sospensione di Selective Serotonin Reuptake Inhibitors (SSRI) o di Serotonin Norepinephrine Reuptake Inhibitors (SNRI) si possono verificare molti fenomeni clinici. Nel 2015, è stata delineata una nuova classificazione delle sindromi d’astinenza da SSRI/SNRI (cioè, nuovi sintomi, rimbalzo, disturbi persistenti post-astinenza) sulla base della letteratura e delle osservazioni cliniche. Un’intervista clinica semistrutturata, la Diagnostic clinical Interview for Drug Withdrawal 1 - New Symptoms of SSRI and SNRI (DID-W1), è stata sviluppata allo scopo di identificare e differenziare queste sindromi. La sua affidabilità fra valutatori è stata testata. Metodi. Diciassette pazienti ambulatoriali consecutivi con una storia di riduzione o sospensione di SSRI o SNRI sono stati valutati indipendentemente da 2 clinici in tempi diversi dello stesso giorno. La percentuale di accordo, il kappa di Cohen e il quadrato del coefficiente di correlazione sono stati utilizzati per misurare l’affidabilità fra i valutatori. Risultati. La percentuale di accordo fra i valutatori relativamente all’intera intervista è risultata pari al 97,06%, il kappa di Cohen è risultato pari all’0,85 (IC95% di 0,61-1,08), il quadrato del coefficiente di correlazione è risultato pari all’0,72. Discussione e conclusioni. I valori di kappa indicano un eccellente accordo fra i valutatori. Sono opportune ulteriori indagini sulla validità e confronti con altri strumenti. La DID-W1 può aiutare a diagnosticare i fenomeni clinici collegati alla sospensione di SSRI e SNRI, a differenziarli dalla ricaduta e a identificare l’origine potenzialmente iatrogena dei sintomi psichiatrici nella pratica clinica.

PAROLE CHIAVE: astinenza, inibitori selettivi della ricaptazione della serotonina, inibitori della ricaptazione di serotoninina e noradrenalina, intervista, affidabilità, comorbilità iatrogena.
INTRODUCTION

In 1968, Di Mascio and Shader introduced the concept of behavioral toxicity of psychotropic medications which referred to the pharmacologic actions of a drug that, within the range in which it has been found to possess clinical utility, may produce alterations in mood, perceptual, cognitive, and psychomotor functions that limit the capacity of the individual or constitute a hazard to well-being\(^1,3\). In 1980, Perl and co-authors reviewed this concept discussing the mechanisms by which psychotropic drugs can cause adverse reactions, that is through the extension of their primary therapeutic action and/or the onset of secondary actions as well as withdrawal, dependence, and tolerance symptoms\(^4\). The concept of drug-induced illness was reported by Chouinard et al.\(^5,6\) during antipsychotic withdrawal or switch, using the model of neuroleptic-induced tardive dyskinesia with the sub-types of withdrawal, overt, masked, and persistent\(^7\). The same concepts were applied to antidepressant withdrawal\(^8,9\) and Fava et al.\(^10\) defined a form of behavioral toxicity as iatrogenic comorbidity providing differentiation between adverse or emergent events that are limited to the period of psychotropic drug administration and effects that may persist long after drug discontinuation\(^10\). They suggested that psychotropic drug treatment, particularly after long-term use, may increase the risk of experiencing additional psychological problems or of modifying responsiveness to subsequent treatments\(^11\).

There is a consistent body of knowledge that indicates that dose reduction or discontinuation of Selective Serotonin Reuptake Inhibitors (SSRI) or Serotonin Norepinephrine Reuptake Inhibitors (SNRI) induces a number of clinical phenomena (i.e., withdrawal or discontinuation syndromes, rebound symptoms, persistent post-withdrawal disorders) both in adults and in children\(^12-20\). There have been various definitions\(^17,21,22\) as well as diagnostic criteria\(^13,24\) of these clinical phenomena. In 2015, a comprehensive and new classification of SSRIs/SNRIs withdrawal phenomena was outlined and specific diagnostic criteria were proposed\(^9\), they allow to formulate the diagnosis of three different syndromes: new symptoms, rebound, persistent post-withdrawal disorders\(^9\) (Table 1). The prevalence of these syndromes is not known at the moment, due to their very recent definition and a lack of diagnostic tools.

### METHODS

**Instrument**

The Diagnostic Clinical Interview for Drug Withdrawal 1 - New Symptoms of SSRI and SNRI, identified with the acronym DID-W1, is a brief semi-structured clinical interview which allows the diagnosis of withdrawal of SSRI or SNRI according to Chouinard & Chouinard\(^9\). It is conducted as a clinical interview by a properly trained clinician and is divided in five modules:

- the first module (named DID-W1-PD) includes 13 questions collecting socio-demographic (e.g., date of birth, sex, civil status, education) or clinical information (i.e., current psychiatric disorder, current psychotropic medication use);
- the second module (named DID-W1-SQ) includes screening questions on the lifetime use of SSRI/SNRI (2 general questions and 4 questions for each SSRI/SNRI used);
- the third module (named DID-W1-WS1) allows to formulate the diagnosis of current as well as lifetime new symptoms (26 questions in section a, 27 questions in section b);
- the fourth module (named DID-W1-WS2) allows to formulate the diagnosis of current as well as lifetime rebound (14 questions in section a, 15 questions in section b);
- the fifth module (named DID-W1-WS3) allows to formulate the diagnosis of current as well as lifetime persistent post-withdrawal disorders (12 questions in section a, 13 questions in section b).

---

Table 1. Withdrawal syndromes according to Chouinard & Chouinard's criteria\(^9\): new symptoms, rebound, persistent post-withdrawal disorders.

<table>
<thead>
<tr>
<th><strong>New symptoms</strong></th>
<th>Symptoms not present before the beginning of the SSRI/SNRI treatment and before reduction or discontinuation of the drug</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>• short-lasting</td>
</tr>
<tr>
<td></td>
<td>• reversible</td>
</tr>
<tr>
<td></td>
<td><em>Unspecific symptoms: nausea, headaches, tremor, sleep disturbances, decreased concentration, anxiety, irritability, agitation/aggression, depression/dysphoria</em></td>
</tr>
<tr>
<td></td>
<td><em>Specific serotonin-related symptoms: flu-like (e.g., flu), cardiovascular (e.g., tachycardia), gastrointestinal (e.g., diarrhea), neuromuscular (e.g., myoclonus), sensory (e.g., electric shock sensations), cognitive (e.g., confusion), sexual (e.g., premature ejaculation)</em></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>Rebound</strong></th>
<th>The return of symptoms which were present before the beginning of the SSRI/SNRI treatment but not present before reduction or discontinuation of the drug</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>• more intense than before treatment</td>
</tr>
<tr>
<td></td>
<td>• rapid</td>
</tr>
<tr>
<td></td>
<td>• transient</td>
</tr>
<tr>
<td></td>
<td>• reversible</td>
</tr>
<tr>
<td></td>
<td>• may be associated to the psychological belief of the need of the drug</td>
</tr>
<tr>
<td></td>
<td>• improve rapidly after reintroduction of the drug</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>Persistent post-withdrawal disorders</strong></th>
<th>The return of symptoms which were present before the beginning of the SSRI/SNRI treatment but were not present before reduction or discontinuation of the drug or of the return of the original illness with additional symptoms (e.g., melancholic features for depression) or appearance of symptoms related to emerging new mental disorders</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>• persist longer than 6 weeks after dose reduction or drug discontinuation</td>
</tr>
<tr>
<td></td>
<td>• have greater intensity than before treatment</td>
</tr>
<tr>
<td></td>
<td>• partially or totally reversible</td>
</tr>
<tr>
<td></td>
<td>• respond partially or totally to reintroduction of discontinued drug</td>
</tr>
</tbody>
</table>

---
We designed the D-ID-W1, the first diagnostic interview for identifying and differentiating drug withdrawal. It was based on the new diagnostic criteria proposed by Chouinard & Chouinard taking as model the withdrawal syndromes associated with all psychotropic drugs including narcotics, hypnotics, anxiolytics, and drugs given in medicine to treat for example high blood pressure. This semi-structured clinical interview aims at formulating the diagnosis of new symptoms, rebound, and persistent postwithdrawal disorders according to the diagnostic criteria by Chouinard & Chouinard. This is the first study testing the psychometric properties of the D-ID-W1, inter-rater reliability results are here presented.
RESULTS

The percent agreement for the whole interview was 97.06%, the Cohen’s kappa was 0.85 (SE=0.083) with a 95% CI of 0.61-1.08, the squared correlation coefficient was 0.72. Inter-rater concordance was excellent. Table 3 reports the percent agreement, the Cohen’s kappa with 95% CI, and the squared correlation coefficient for each diagnosis.

DISCUSSION

A kappa value above 0.80 indicates excellent inter-rater agreement and suggests that the DID-W1 is a reliable method for diagnostic evaluation in SSRI/SNRI withdrawal syndromes.

This is the first tool designed to identify and classify the various clinical manifestations that are associated with SSRI and SNRI discontinuation, according to Chouinard & Chouinard’s9 diagnostic criteria. The most widely used method for assessing such phenomena has been for a long time the Discontinuation Emergence Signs and Symptoms (DESS)44, a checklist of signs and symptoms of withdrawal with no diagnostic purposes, even though the patients may be classified as experiencing a withdrawal syndrome if the number of DESS checklist events increased by four or more during the discontinuation period.

The DID-W1 is an interview which may have a number of important clinical and research implications. First, it is a tool for identifying and differentiating the clinical phenomena that may occur on SSRI and SNRI discontinuation. Not surprisingly, there is a wide variation (between 14 and 78%) on the incidence of withdrawal symptoms after dose reduction, discontinuation, or switch of SSRIs or SNRIs45. It may depend on drug differences and on the samples that are studied, but also on the lack of suitable diagnostic instruments. Second, it may help differentiating withdrawal phenomena from relapse9,42. In clinical practice, lack of appraisal of withdrawal phenomena may lead to inappropriate clinical decisions, such as unnecessary re-institution of drug treatment. In research, it may allow to differentiate between withdrawal phenomena and relapse after antidepressant discontinuation, which would otherwise be impossible to discern43; it may yield a full assessment of side effects of antidepressant drugs41; it may lead to a correct identification of distress and use of antidepressants in epidemiological studies44. Finally, psychiatric symptoms in clinical practice may also be a consequence of previous pharmacological treatments, the so called iatrogenic comorbidity, that would require removal of the drug but is more often interpreted as a justification for new treatment41.

It is hoped that the DID-W1 will encourage studies on this topic and may lead to a refinement of patients’ assessment, as well as treatment, in clinical settings. There is however the need for other reliability studies on the DID-W1 such as comparisons with the DESS as well as construct validity studies. There is also need of similar semi-structured interviews to be produced for classifying withdrawal syndrome related to other drugs, such as antipsychotics25.

**Acknowledgment:** The copyright of the DID-W1 The Diagnostic Clinical Interview for Drug Withdrawal 1 - New Symptoms of SSRI and SNRI was deposited by the University of Florence (Italy), at the request of Fiammetta Cosci and on the basis of a copyright management agreement with Guy Chouinard. Harvard Medical School (as what concerns Virginia-Anne Chouinard), and University of Bologna (as what concerns Giovanni Andrea Fava).

**Formatting of funding resources:** this research did not receive any specific grant funding agencies in the public, commercial, or not-for-profit sectors.

**REFERENCES**


**Table 3. Inter-rater reliability per diagnosis.**

<table>
<thead>
<tr>
<th>Diagnosis</th>
<th>% of agreement</th>
<th>Cohen’s kappa (SE)</th>
<th>95% CI</th>
<th>Squared correlation coefficient</th>
</tr>
</thead>
<tbody>
<tr>
<td>Current new withdrawal symptoms</td>
<td>100.00</td>
<td>1.00 (0.00)</td>
<td>-</td>
<td>1</td>
</tr>
<tr>
<td>Lifetime new withdrawal symptoms</td>
<td>88.23</td>
<td>0.72 (0.18)</td>
<td>0.15-1.29</td>
<td>0.51</td>
</tr>
<tr>
<td>Current rebound withdrawal symptoms</td>
<td>100.00</td>
<td>1.00 (0.00)</td>
<td>-</td>
<td>1</td>
</tr>
<tr>
<td>Lifetime rebound withdrawal symptoms</td>
<td>94.11</td>
<td>0.63 (0.33)</td>
<td>-0.34-1.60</td>
<td>0.40</td>
</tr>
<tr>
<td>Current persistent post-withdrawal disorder</td>
<td>100.00</td>
<td>1.00 (0.00)</td>
<td>-</td>
<td>1</td>
</tr>
<tr>
<td>Lifetime persistent post-withdrawal disorder</td>
<td>100.00</td>
<td>1.00 (0.00)</td>
<td>-</td>
<td>1</td>
</tr>
</tbody>
</table>


Kay SR, Eiselein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 1987; 13: 261-76.


Carvalho AF, Sharma MS, Brunoni AR, Vieta E, Fava GA. The safety, tolerability and risks associated with the use of newer-generation antidepressant drugs: a critical review of the literature. Psychother Psychosom 2016; 85: 270-88.

Fava GA, Rational use of antidepressant drugs. Psychother Psychosom 2014; 83: 197-204.


